SCOTUS sides with Sanofi and Regeneron in PCSK9 patent dispute against Amgen.

The US Supreme Court has ruled unanimously in favor of Sanofi and Regeneron in a patent dispute with Amgen over PCSK9, stating that Amgen cannot monopolize the market for any and every antibody that binds to areas of the sweet spot of PCSK9. The ruling is a setback for companies like Amgen who are looking to patent broad categories of antibodies.